The present invention relates to novel hepcidin antagonists of formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for treatment of disorders in iron metabolism, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases (ACD: anaemia of chronic disease and AI: anaemia of inflammation).
A stereoselectivehypervalent iodine-promoted oxidative rearrangement of 1,1-disubstituted alkenes has been developed. This practically simple protocol provides access to enantioenriched α-arylated ketones without the use of transition metals from readily accessible alkenes.
In the presence of a catalytic amount of bis[1,3-di(p-methoxyphenyl)-1,3-propanedionato]nickel(II) (=Ni(dmp)2), various olefins are smoothly monooxygenated into corresponding epoxides in good yields with combined use of molecularoxygen and primary alcohol.